- Innovative clinic establishes new patient-first model for
Colombia with the benefits of
complementary professional medical services in a single, integrated
care environment
- Clinic features contemporary design across four expansive
floors, within 600 metres of Bogota's largest transit hub, and in the
city's prime medical services district
- 15,000 sq. ft clinic offers comprehensive suite of health and
medical services in alignment with insurance company partners
- Zerenia launch follows the successful growth of Company's Ilans
neurological clinics
- Zerenia branded clinic in keeping with Khiron's patient
acquisition strategy as Company prepares for cannabis prescriptions
in Colombia
TORONTO, Jan. 14, 2020 /CNW/ - Khiron Life Sciences Corp.
("Khiron" or the "Company") (TSXV: KHRN), (OTCQB: KHRNF),
(Frankfurt: A2JMZC), a vertically
integrated cannabis leader with core operations in Latin America, today announced the opening of
Zerenia, a fully integrated medical care clinic designed to meet
patient health and well-being. Operating in a 15,000 sq. ft
facility in Bogota's prime medical
services district, the clinic increases Khiron's clinical capacity
by 75% and forms part of the Company's patient acquisition strategy
as it prepares for the issue of cannabis prescription in
Colombia.
Zerenia offers a person-centered integrated care model, with the
concept of integrative medicine combining traditional and
complementary medicine, and with evidence-based treatments and high
professional practices. Services are delivered across multiple
clinical units include: Pain management, mental health, surgical,
neurology and dentistry, supported by rehabilitation, complementary
medicine and diagnostic technology, involving programs for managing
multiple symptoms in different pathologies. Prominently located in
Bogota's city centre, Zerenia
builds on the integration and growth of the Company's wholly-owned
Ilans neurological clinics and its over 60 physicians, and is
staffed by a team of health professionals and clinical leaders
representing different specialties.
Phase one of the 15,000 sq. ft clinic is open for treatments and
phase two will be ready to receive patients in March 2020.
"We are excited to be opening Zerenia in Bogota, a busy city of more than 10 million
people and a population increasingly demanding convenient, one-stop
access to medical care of the highest professional standards. In a
state of the art clinic, our physicians and health care
professionals will consult with patients and offer appropriate
treatment therapies." Comments Martha Edith Oyuela, Khiron
Health Vice President. "For the first time patients will have
access to an array of integrated professional, patient-centred
options."
"Our strategy in launching Zerenia is to meet a very clear
market need to treat the whole patient in one professional
environment. With the success of our Ilans clinics, and the growing
movement towards integrated medical care, we are leading the market
in bringing this concept to Colombia. This strategy further expands our
reach to bring patients into the Khiron network, including those
that are well suited for cannabis therapies." Adds Khiron CEO and
Director Alvaro Torres.
About Khiron Life Sciences Corp.
Khiron Life Sciences
Corp. is positioned to be the dominant integrated cannabis company
in Latin America. Khiron has core
operations in Latin America and is
fully licensed in Colombia for the
cultivation, production, domestic distribution, and international
export of both tetrahydrocannabinol (THC) and cannabidiol (CBD)
medical cannabis. The company delivers best in class regulatory
compliance, has the first approved set of CBD cosmetic products on
shelf in Colombia, and is currently facilitating testing to
meet and surpass all license requirements for commercial cannabis
derived products.
With a focused regional strategy and patient oriented
approach, the Company combines global scientific expertise,
agricultural advantages, branded product market entrance
experience and education to drive prescription and brand
loyalty to address priority medical conditions such as chronic
pain, epilepsy, depression and anxiety in the Latin American
market of over 620 million people. The Company is led by Co-founder
and Chief Executive Officer, Alvaro
Torres, together with an experienced executive team,
and a knowledgeable Board of Directors that includes former
President of Mexico, Vicente Fox.
Visit Khiron online at www.khiron.ca and on Instagram
@khironlife
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment analyses,
expectations or statements made by third-parties in respect of
Khiron, its securities, or financial or operating results (as
applicable). Although Khiron believes that the expectations
reflected in forward-looking statements in this press release are
reasonable, such forward-looking statement has been based on
expectations, factors and assumptions concerning future events
which may prove to be inaccurate and are subject to numerous risks
and uncertainties, certain of which are beyond Khiron's control,
including the risk factors discussed in Khiron's Annual Information
Form which is available on Khiron's SEDAR profile
at www.sedar.com. The forward-looking information contained in
this press release is expressly qualified by this cautionary
statement and are made as of the date hereof. Khiron disclaims any
intention and has no obligation or responsibility, except as
required by law, to update or revise any forward-looking
information, whether as a result of new information, future events
or otherwise.
United States Disclaimer
This news release does not constitute an offer to sell or a
solicitation of an offer to buy any of the securities
in the United States. The securities have not been and
will not be registered under the United States Securities Act of
1933, as amended (the "U.S. Securities Act") or any state
securities laws and may not be offered or sold within the
United States or to U.S. Persons
(as such term is defined in Regulation S under the U.S. Securities
Act) unless registered under the U.S. Securities Act and applicable
state securities laws or an exemption from such registration is
available
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/khiron-increases-clinical-capacity-in-colombia-by-75-with-opening-of-zerenia-integrated-medical-clinic-300986247.html
SOURCE Khiron Life Sciences Corp.